Background: Covid-19 has spread its wings over the globe, claiming numerous lives. The virus that causes this is by severe acute respiratory syndrome coronavirus-2. Data from numerous nations suggest that people with comorbid diseases have a higher morbidity and death rate (diabetes, hypertension, cardiovascular illness) Aim: We wanted to offer a better knowledge of the coronavirus disease in persons with diabetes and its management by providing a quick assessment of the general features of the novel coronavirus. In this review explore the possible danger of medication interactions between drugs used to treat covid-19 infection and drugs used to manage diabetes. Method: We looked for publications with the following keywords in PubMed and Google Scholar databases till 20 May 2022: SARS-CoV-2, COVID-19, infection, pathophysiology, incubation period, transmission. SARS Cov-2 variations, clinical characteristics, diagnosis, COVID-19 prevention, therapy, and review papers about diabetes patients with covid-19. Result: COVID-19 has a broad clinical range, ranging from mild flu-like symptoms to acute respiratory distress syndrome, multiple organ failure, and death. Based on the evidence, many antiviral anti-inflammatory drugs have been approved by the Food and Drug Administration to treat covid-19 patients even though not knowing the possible drug-drug interaction and the fact that the potential drug-drug interaction of covid-19 drugs in diabetic patients result in worsening glycaemic control. Older age, diabetes, and other comorbidities have all been identified as important predictors of morbidity and death. Conclusion: The findings of this study show that covid-19 patients with diabetes had a higher risk of severity, due to drug-drug interaction, and that this primary evidence may consideration the severity, morbidity and mortality of covid-19 patients, based on the mechanism of the relationship between anti-diabetic and covid-19 drugs, which are worsening of glycaemic control.